Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: role of echocardiography

J Cardiovasc Med (Hagerstown). 2016 May:17 Suppl 1:e35-e44. doi: 10.2459/JCM.0000000000000374.

Abstract

The evaluation by cardiovascular imaging of chemotherapy patients became a central topic in the last several years. The use of drugs for the treatment of cancers increased, and new molecules and protocols were developed to improve outcomes in these patients. Although, these novel approaches also produced a progressive increase in side effects, particularly myocardial dysfunction. Imaging of the heart was highly accurate in the early diagnosis of cancer therapeutics related-cardiac dysfunction. Echocardiography is the first-line method to assess ventricular function alterations, and it is required to satisfy the need for an early, easy and accurate diagnosis to stratify the risk of heart failure and manage treatments. A careful monitoring of cardiac function during the course of therapy should prevent the onset of severe heart impairment. This review provides an overview of the most important findings of the role of echocardiography in the management of chemotherapy-treated patients to create a clear and complete description of the efficacy of conventional measurements, the importance of comprehensive heart evaluations, the additional role of new echocardiographic techniques, the utility of integrated studies using other imaging tools and the positions of the most important international societies on this topic.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Cardiotoxicity / diagnostic imaging
  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / diagnostic imaging*
  • Early Diagnosis
  • Echocardiography, Doppler, Color
  • Echocardiography, Three-Dimensional
  • Heart / drug effects
  • Heart / physiopathology*
  • Humans
  • Neoplasms / drug therapy
  • Ventricular Function / drug effects

Substances

  • Antineoplastic Agents